Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women

被引:43
|
作者
Min, SS
Corbett, AH
Rezk, N
Cu-Uvin, S
Fiscus, SA
Petch, L
Cohen, MS
Kashuba, ADM
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[5] Brown Univ, Sch Med, Providence, RI 02912 USA
关键词
female genital tract; pharmacokinetic; antiretroviral concentration; HIV-1; protease inhibitor; nonnucleoside reverse transcriptase inhibitor;
D O I
10.1097/00126334-200412150-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.
引用
收藏
页码:1577 / 1580
页数:4
相关论文
共 50 条
  • [21] Safety and Efficacy of GSK2248761, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive HIV-1-Infected Subjects
    Zala, Carlos
    St Clair, Marty
    Dudas, Kathleen
    Kim, Joseph
    Lou, Yu
    White, Scott
    Piscitelli, Steve
    Dumont, Etienne
    Pietropaolo, Keith
    Zhou, Xiao-Jian
    Mayers, Douglas
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) : 2570 - 2575
  • [22] PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY A NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR
    SCHLEIF, WA
    SARDANA, VV
    BYRNES, VW
    MURTHY, KK
    EMINI, EA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 23 - 23
  • [23] Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability
    Figueiredo, Anna
    Zelina, Shannon
    Sluis-Cremer, Nicolas
    Tachedjian, Gilda
    CURRENT HIV RESEARCH, 2008, 6 (02) : 130 - 137
  • [24] Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients
    Llibre-Codina, Josep Maria
    Casado-Gomez, Miguel Angel
    Sanchez-de la Rosa, Rainel
    Perez-Elias, Maria Jesus
    Santos-Gonzalez, Jesus
    Miralles-Alvarez, Celia
    Martinez-Chamorro, Esteban
    Domingo-Pedrol, Pere
    Alvarez-Garcia, Maria Luisa
    Moreno-Guillen, Santiago
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2007, 25 (02): : 98 - 107
  • [25] A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy
    Lake, Jordan E.
    McComsey, Grace A.
    Hulgan, Todd M.
    Wanke, Christine A.
    Mangili, Alexandra
    Walmsley, Sharon L.
    Boger, M. Sean
    Turner, Ralph R.
    McCreath, Heather E.
    Currier, Judith S.
    AIDS PATIENT CARE AND STDS, 2012, 26 (09) : 532 - 540
  • [26] Lipid Metabolism and Lipodystrophy in HIV-1-Infected Patients: The Role Played by Nonnucleoside Reverse Transcriptase Inhibitors
    Sension, Michael
    Deckx, Henri
    AIDS REVIEWS, 2015, 17 (01) : 21 - 36
  • [27] Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients
    von Giesen, HJ
    Köller, H
    Theisen, T
    Arendt, G
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 (04) : 363 - 367
  • [28] CYP2B6 Polymorphism and Nonnucleoside Reverse Transcriptase Inhibitor Plasma Concentrations in Chinese HIV-Infected Patients
    Chen, Jun
    Sun, Jianjun
    Ma, Qing
    Yao, Yaming
    Wang, Zhenyan
    Zhang, Lijun
    Li, Li
    Sun, Fuyan
    Lu, Hongzhou
    THERAPEUTIC DRUG MONITORING, 2010, 32 (05) : 573 - 578
  • [29] Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
    Moyo, Sikhulile
    Gaseitsiwe, Simani
    Zahralban-Steele, Melissa
    Maruapula, Dorcas
    Nkhisang, Tapiwa
    Mokaleng, Baitshepi
    Mohammed, Terence
    Ditlhako, Tsotlhe R.
    Bareng, Ontlametse T.
    Mokgethi, Thatayaone P.
    van Widenfelt, Erik
    Pretorius-Holme, Molly
    Mine, Madisa O.
    Raizes, Elliot
    Yankinda, Etienne Kadima
    Wirth, Kathleen E.
    Gaolathe, Tendani
    Makhema, Joseph M.
    Lockman, Shahin
    Essex, Max
    Novitsky, Vlad
    AIDS, 2019, 33 (06) : 1073 - 1082
  • [30] Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase
    Peter M. Grob
    Yunzhen Cao
    Elizabeth Muchmore
    David D. Ho
    Steve Norris
    Joseph W. Pav
    Cheng-Kon Shih
    Julian Adams
    Nature Medicine, 1997, 3 : 665 - 670